FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023644079> ?p ?o ?g. }

• W2023644079 endingPage "81" @default.
• W2023644079 startingPage "77" @default.
• W2023644079 abstract "Purpose: To prospectively assess the health-related quality of life (HRQOL) and changes in HRQOL during the first year after permanent source interstitial brachytherapy (PIB).Methods and Materials: Thirty-one men treated with PIB between September 1997 and March 1998 completed a quality of life (functional assessment of cancer therapy-prostate: FACT-P) and a urinary symptom questionnaire (international prostate symptom score: IPSS) prior to treatment (T0), 1 month (T1), 3 months (T3), 6 months (T6), and 12 months (T12) following PIB. All participants were treated with 125I alone. Repeated measures analyses of variance (ANOVA) were conducted on all quality of life and urinary outcome measures for all 31 patients at all time points.Results: The median age of the study population was 66 (range 51–80). All men had clinical T1c–T2b prostate cancer. The Gleason score was ≤ 6 in 27/31 (87%). Median pretreatment PSA was 7.8 ng/ml (range 1.1–20.6). The mean score (and standard deviation) at T0, T1, T3, T6, and T12 for the FACT-P questionnaire are as follows: 140.5 (13.5), 132.7 (15.3), 137.2 (17.4), 140.1 (16.0), and 142.4 (15.3). For the global test across time, statistically significant differences were observed for the cumulative scores of FACT-P (p < 0.0012). The decrease in HRQOL was most marked 1 month following PIB. Examination of the subscales within the FACT-P instrument demonstrated statistically significant changes over time for the following: physical well-being (PWB), functional well-being (FWB), and prostate cancer (PCS). By 3 months, all HRQOL measures had returned to near baseline. The mean score (and standard deviation) at T0, T1, T3, T6, and T12 for the IPSS questionnaire are as follows: 8.3 (5.5), 18.4 (8.0), 15.7 (7.4), 13.7 (7.4), and 10.2 (5.7). For the global test across time, statistically significant differences were observed for the IPSS scores (p < 0.0001). The maximum increase in IPSS occurred 1 month following PIB.Conclusion: The results of this preliminary analysis suggest that clinically meaningful decreases in HRQOL, as measured by the FACT-P instrument, are evident within weeks after PIB. By 3 months, however, FACT-P scores return to near baseline levels. A validated instrument designed to measure urinary symptoms (IPSS) demonstrates that moderate to severe urinary symptoms persist for at least 3–6 months following PIB. One year following PIB, the scores on the FACT-P and IPSS questionnaires had returned to baseline." @default.
• W2023644079 created "2016-06-24" @default.
• W2023644079 creator A5001088387 @default.
• W2023644079 creator A5042766411 @default.
• W2023644079 creator A5051750036 @default.
• W2023644079 creator A5053343870 @default.
• W2023644079 creator A5059803474 @default.
• W2023644079 date "2000-01-01" @default.
• W2023644079 modified "2023-10-17" @default.
• W2023644079 title "A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer" @default.
• W2023644079 cites W1771200015 @default.
• W2023644079 cites W1875462884 @default.
• W2023644079 cites W1966152963 @default.
• W2023644079 cites W1975020079 @default.
• W2023644079 cites W1978663841 @default.
• W2023644079 cites W2004909463 @default.
• W2023644079 cites W2008041428 @default.
• W2023644079 cites W2011521785 @default.
• W2023644079 cites W2014725195 @default.
• W2023644079 cites W2020018804 @default.
• W2023644079 cites W2025674066 @default.
• W2023644079 cites W2027250412 @default.
• W2023644079 cites W2029631561 @default.
• W2023644079 cites W2029725065 @default.
• W2023644079 cites W2068776651 @default.
• W2023644079 cites W2105258029 @default.
• W2023644079 cites W2150846672 @default.
• W2023644079 cites W2993539218 @default.
• W2023644079 doi "https://doi.org/10.1016/s0360-3016(99)00355-7" @default.
• W2023644079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10656376" @default.
• W2023644079 hasPublicationYear "2000" @default.
• W2023644079 type Work @default.
• W2023644079 sameAs 2023644079 @default.
• W2023644079 citedByCount "64" @default.
• W2023644079 countsByYear W20236440792013 @default.
• W2023644079 countsByYear W20236440792014 @default.
• W2023644079 countsByYear W20236440792015 @default.
• W2023644079 countsByYear W20236440792017 @default.
• W2023644079 countsByYear W20236440792020 @default.
• W2023644079 countsByYear W20236440792021 @default.
• W2023644079 crossrefType "journal-article" @default.
• W2023644079 hasAuthorship W2023644079A5001088387 @default.
• W2023644079 hasAuthorship W2023644079A5042766411 @default.
• W2023644079 hasAuthorship W2023644079A5051750036 @default.
• W2023644079 hasAuthorship W2023644079A5053343870 @default.
• W2023644079 hasAuthorship W2023644079A5059803474 @default.
• W2023644079 hasConcept C102959455 @default.
• W2023644079 hasConcept C105795698 @default.
• W2023644079 hasConcept C121608353 @default.
• W2023644079 hasConcept C126322002 @default.
• W2023644079 hasConcept C126894567 @default.
• W2023644079 hasConcept C159110408 @default.
• W2023644079 hasConcept C2776235491 @default.
• W2023644079 hasConcept C2776547966 @default.
• W2023644079 hasConcept C2777416452 @default.
• W2023644079 hasConcept C2779478474 @default.
• W2023644079 hasConcept C2779951463 @default.
• W2023644079 hasConcept C2780192828 @default.
• W2023644079 hasConcept C2908647359 @default.
• W2023644079 hasConcept C33923547 @default.
• W2023644079 hasConcept C509974204 @default.
• W2023644079 hasConcept C71924100 @default.
• W2023644079 hasConcept C99454951 @default.
• W2023644079 hasConcept C99476002 @default.
• W2023644079 hasConceptScore W2023644079C102959455 @default.
• W2023644079 hasConceptScore W2023644079C105795698 @default.
• W2023644079 hasConceptScore W2023644079C121608353 @default.
• W2023644079 hasConceptScore W2023644079C126322002 @default.
• W2023644079 hasConceptScore W2023644079C126894567 @default.
• W2023644079 hasConceptScore W2023644079C159110408 @default.
• W2023644079 hasConceptScore W2023644079C2776235491 @default.
• W2023644079 hasConceptScore W2023644079C2776547966 @default.
• W2023644079 hasConceptScore W2023644079C2777416452 @default.
• W2023644079 hasConceptScore W2023644079C2779478474 @default.
• W2023644079 hasConceptScore W2023644079C2779951463 @default.
• W2023644079 hasConceptScore W2023644079C2780192828 @default.
• W2023644079 hasConceptScore W2023644079C2908647359 @default.
• W2023644079 hasConceptScore W2023644079C33923547 @default.
• W2023644079 hasConceptScore W2023644079C509974204 @default.
• W2023644079 hasConceptScore W2023644079C71924100 @default.
• W2023644079 hasConceptScore W2023644079C99454951 @default.
• W2023644079 hasConceptScore W2023644079C99476002 @default.
• W2023644079 hasIssue "1" @default.
• W2023644079 hasLocation W20236440791 @default.
• W2023644079 hasLocation W20236440792 @default.
• W2023644079 hasOpenAccess W2023644079 @default.
• W2023644079 hasPrimaryLocation W20236440791 @default.
• W2023644079 hasRelatedWork W1980188241 @default.
• W2023644079 hasRelatedWork W1980245127 @default.
• W2023644079 hasRelatedWork W2048085960 @default.
• W2023644079 hasRelatedWork W2062703397 @default.
• W2023644079 hasRelatedWork W2127440557 @default.
• W2023644079 hasRelatedWork W2165532162 @default.
• W2023644079 hasRelatedWork W2590008096 @default.
• W2023644079 hasRelatedWork W2810968949 @default.
• W2023644079 hasRelatedWork W2897445903 @default.
• W2023644079 hasRelatedWork W56824131 @default.
• W2023644079 hasVolume "46" @default.

• next